Genmab — December 2020
-
ØU: Genmab: KapitalmarKedsdaG oG optaKt til asH / side 1nr. 21– 03. december 2020 – 6. årGanGEfter en veloverstået kapitalmarkedsdag og med usikkerheden fra den igangværende Darzalex-voldgiftssag in mente (Life Science 16/2020) fastholder vi vores 12-måneders kursmål på 2.700 DKK her på tærsklen til en spændende ASH-konference.
-
God analyse af David Mygind:-)
-
Genmab: Vigtige begivenheder på ASH 2020: https://www.proinvestor.com/index.php?p=debat_1&postid=89033
-
Enig GB.
-
Tror ikke der er nogen udover JNJ/Genmab der kender satsen præcist. Men de fleste regner med 10%, da begge ben i duobodyen er Gemmab udviklede
-
Dr Mark Wildgust on What to Look for From Janssen at ASH https://www.ajmc.com/view/dr-mark-wildgust-on-what-to-look-for-from-janssen-at-ash
-
https://twitter.com/Genmab/status/1334543693458628612 epcoritamab video, we saw it before, but if you watch it often enough, you understand more and more of it

-
Ja, hvis epco data viser sig at være bedre end de tilsvarende fra Roche
-
Der er ikke meget hype over den i dag. Lad os håbe JvdW får ret:-)
-
Solen skinner altid...oven over alt ting...:-)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind